Skip to main content

Origin and Programming of Fetal Group 1 Lymphoid Cells

Fellow: Emily Kulp

Mentor: Brian Rudd

Department of Microbiology and Immunology
Sponsor: NIH-National Institute of Allergy and Infectious Diseases (NIAID)
Grant Number: 1F30AI203419-01
Title: Origin and Programming of Fetal Group 1 Lymphoid Cells
Project Amount: $44,452
Project Period: February 2027 to February 2028

DESCRIPTION (provided by applicant):

Over the last two decades there has been a growing appreciation for the unique contributions of fetal hematopoiesis to the immune system. We now know that early fetal progenitors are capable of producing B cells, T cells, and macrophages that are functionally distinct from their hematopoietic stem cell (HSC)-derived counterparts. By contrast, our understanding of natural killer (NK) and type 1 innate lymphoid cell (ILC1) development is much more limited. This is a crucial knowledge gap, especially considering the important role that NK and ILC1s–collectively termed group 1 innate lymphoid cells (ILC)–play in controlling infection and cancer. There is some evidence that fetal-derived group 1 ILCs possess unique functions compared to their counterparts generated in adulthood. However, the specific embryonic progenitors that produce fetal-derived group 1 ILCs and the molecular regulators that underlie their development have yet to be clearly defined. Interestingly, my preliminary data suggests that fetal-derived group 1 ILCs arise from hemogenic endothelial cells in the yolk sac prior to the emergence of HSCs. Moreover, I found that forced expression of Lin28b enables adult HSCs to give rise to group 1 ILCs that behave similarly to those found in neonates. Based on these data, I hypothesize that Lin28b expression in HSC-independent progenitors promotes the development of fetal-derived group 1 ILCs. In Aim 1, I will use in vitro artificial organoids and in vivo approaches to map the development of group 1 ILCs from various embryonic progenitors. In Aim 2, I will use Lin28b knockout and transgenic mouse models to determine the necessity and sufficiency of Lin28b in programming fetal group 1 ILC functions. Throughout this project, I will receive integrated training from an innovative team of scientific and clinical mentors that will position me to launch a successful career in translational immunology research. Altogether, my findings will advance our understanding of how fetal origins shape early life immunity and provide novel genetic targets that tailor group 1 ILC functions to better fight off disease.